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Bart syndrome was first described by Bart et al. in 1966 with a constellation of congenital localised absence of skin (CLAS), congenital epidermolysis bullosa (EB) and associated nail abnormalities.1 This article reports a case of Bart syndrome with ear malformation in a female Egyptian 
Figure 1A–E: Photographs showing a case of Bart syndrome with ear malformation in a female Egyptian newborn. A: 
Well-demarcated non-inflammatory skin defects covered by a red thin translucent membrane localised to the nose, 
around both wrist joints, the front of the left knee, dorsum of both feet, around both ankle joints and around the lower 
third of the legs. B: Two areas of ulcerations on the back. C: Dysplastic nails and absent skin over the dorsum of the hand, 
sparing the fingertips. D: Malformed ear with attached helix to the underlying skin and small areas of absent skin around 
the ear. E: Dryness and extension of the old skin lesions and the appearance of multiple bullous lesions was noted over 
the upper and lower limbs. 
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newborn. To the best of the authors’ knowledge, this is 
the first report of Bart’s syndrome in an Egyptian family. 
A female preterm newborn (with a gestational 
age of 35 weeks) was referred at birth to the neonatal 
intensive care unit of Suez Canal University Hospital, 
Ismailia, Egypt, in February 2014. She presented 
with multiple areas of congenital CLAS associated 
with nail dystrophy and malformed ears. The parents 
were consanguineous and had previously had 
three daughters with the same condition who had 
subsequently died at the ages of three hours, four 
hours and seven days old, respectively. The current 
neonate was the sixth child born to the couple. 
On physical examination, the newborn showed 
sharply demarcated, bilateral non-inflammatory skin 
defects covered by a red thin translucent membrane 
localised to the dorsum of both hands and around 
both wrist joints, the dorsum of both feet and around 
both ankle joints, around the umbilicus, anterior 
aspect of the left knee and nose [Figure 1A] and 
over the back [Figure 1B]. Dysplastic nails were also 
observed, as well as bilateral malformed ears in the 
form of adherent auricles attached to the underlying 
skin and bilateral hallux hypoplasia [Figures 1C & D]. 
Laboratory investigations revealed a total leukocyte 
count of 2,300/cmm, C-reactive protein levels of 
28 mg/dL, normal blood chemistry and blood gases 
and a negative skin swab for aerobic bacteria. The 
newborn was managed with systemic vancomycin and 
ceftazidime initiated empirically in addition to local 
topical fusidic acid with atraumatic dressings for the 
skin lesions. 
At day of life (DOL) two, the infant began to 
develop disseminated bullous skin lesions mainly over 
the upper and lower limbs and a mucous membrane 
of the mouth. Oozing, dryness and extension were 
observed in the old skin lesions [Figure 1E]. At DOL 
four, the baby developed severe neonatal sepsis with 
depressed activity as well as extensive lesions in the 
lips, on the mucous membranes of the mouth and 
larynx with yellowish endotracheal aspirate. The 
neonate died on DOL four due to severe neonatal 
sepsis, septicshock and metabolic acidosis. The rapid 
progression and fatal course of the disease interrupted 
the planned ultrastructural, immunohistological and 
genetic link-age investigations. 
Comment
Bart syndrome is one type of dominant dystrophic 
EB. In some families, a link to the gene for type VII 
collagen has been demonstrated, suggesting that this 
is the mutational site.2 The diagnosis of aplasia cutis 
congenita, including Bart syndrome, is primarily a 
clinical diagnosis based on the classical cutaneous 
findings; the extent of involvement depends on the 
mode of inheritance.3 In the family of the current 
case, only female infants were affected. This raises 
questions regarding whether gender is involved in the 
phenotypic variation and severity of Bart syndrome. 
This case may therefore support the hypothesis of 
Wakasugi et al., who suggested that the expression of 
symptoms might differ depending on the gender of the 
affected individual.4
The similarity of defects and symptoms in all 
reported cases, as well as in this patient, strongly 
suggests that CLAS in Bart syndrome is not solely 
associated with a mechanical aetiology, but may 
follow Blaschko’s lines, particularly with regards to 
the localisation of lesions to the limbs.5 Other areas 
exposed to friction and trauma, such as the skin around 
the oral cavity, nose and ears, can also be affected. 
Nail changes include congenital absence in terms of 
nail dystrophy or progressive loss.
This reported case of Bart syndrome was 
diagno-sed clinically, postnatally. A skin biopsy is 
essential in establishing an accurate postnatal 
classification of inherited EB. The biopsy sample 
should be examined for a combination of ultra- 
structural and antigenic features by transmission 
electron microscopy, immunofluorescence antigenic 
mapping and EB-related monoclonal antibody 
investigations.6 Fetoscopies have been performed 
successfully to diagnose inherited EB prenatally; fetal 
skin biopsy specimens for ultrastructural analysis are 
obtained via transmission electron microscopy in 
order to identify possible structural defects in the fetal 
skin.7 However, fetal skin biopsies have gradually been 
superseded by DNA-based diagnostic screening using 
fetal DNA from amniotic fluid cells or chorionic villi 
samples.8 Despite a strong family history, a prenatal 
diagnosis in the current patient was not attempted due 
to the expense of the required tests and procedures.
Septicaemia, electrolyte imbalances, protein loss 
and failure to thrive complicate severe exudative 
skin lesions and often lead to death in cases of 
Bart syndrome.9 Septicaemia was also the cause 
of death in this case. Patients with Bart syndrome 
can be successfully treated with the use of topical 
antimicrobial drugs and sterile dressing pads for 
prophylaxis of secondary infections. In infants older 
than two months, the use of silver sulfadiazine cream 
and the early debridement of lesions with closed 
dressings has been shown to improve survival and 
quality of life for affected patients. Rosmaninho et 
al. reported the complete healing of prominent milia 
after three months; however, blistering of the lesions 
recurred.10 Extra-cutaneous involvement has also 
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been observed in survivors, commonly reported as 
mucosal involvement of the gastrointestinal tract, 
genitourinary tract and eyes. Corrective gene therapy is 
the ideal therapy for EB, but more research is required 
prior to its utilisation in clinical practice. Cell-based 
therapies using fibroblasts and bone marrow cells have 
recently attracted considerable attention and may lead 
to effective results.11
References
1. Bart BJ, Gorlin RJ, Anderson VE, Lynch FW. Congenital localized 
absence of skin and associated abnormalities resembling 
epidermolysis bullosa: A new syndrome. Arch Dermatol 1966; 
93:296–304. doi: 10.1001/archderm.1966.01600210032005.
2. Gruis NA, Bavinck JN, Steijlen PM, van der Schroeff JG, van 
Haeringen A, Happle R, et al. Genetic linkage between the 
collagen VII (COL7A1) gene and the autosomal dominant form 
of dystrophic epidermolysis bullosa in two Dutch kindreds. J 
Invest Dermatol 1992; 99:528–30. doi: 10.1111/1523-1747.
ep12658066.
3. Frieden IJ. Aplasia cutis congenita: A clinical review and 
proposal for classification. J Am Acad Dermatol 1986; 14:646–
60. doi: 10.1016/S0190-9622(86)70082-0.
4. Wakasugi S, Mizutari K, Ono T. Clinical phenotype of 
Bart’s syndrome seen in a family with dominant dystrophic 
epidermolysis bullosa. J Dermatol 1998; 25:517–22. 
5. Duran-McKinster C, Rivera-Franco A, Tamayo L, de la Luz 
Orozco-Covarrubias M, Ruiz-Maldonado R. Bart syndrome: 
The congenital localized absence of skin may follow the lines of 
Blaschko - Report of six cases. Pediatr Dermatol 2000; 17:179–
82. doi: 10.1046/j.1525-1470.2000.01747.x.
6. Pfendner EG, Bruckner A, Conget P, Mellerio J, Palisson 
F, Lucky AW. Basic science of epidermolysis bullosa and 
diagnostic and molecular characterization: Proceedings of 
the IInd International Symposium on Epidermolysis Bullosa, 
Santiago, Chile, 2005. Int J Dermatol 2007; 46:781–94. doi: 
10.1111/j.1365-4632.2007.03307.x.
7. Rodeck CH, Eady RA, Gosden CM. Prenatal diagnosis of 
epidermolysis bullosa letalis. Lancet 1980; 1:949–52. doi: 
10.1016/S0140-6736(80)91404-X.
8. Fassihi H, Eady RA, Mellerio JE, Ashton GH, Dopping-
Hepenstal PJ, Denyer JE, et al. Prenatal diagnosis for severe 
inherited skin disorders: 25 years’ experience. Br J Dermatol 
2006; 154:106–13. doi: 10.1111/j.1365-2133.2005.07012.x.
9. Narter F, Büyükbabani N, Yararlı H, Oztürk S, Ergüven M. 
Bart’s syndrome associated with pyloric and choanal atresia. 
Turk J Pediatr 2013; 55:214–17. 
10. Rosmaninho A, Machado S, Selores M. Bart syndrome. Int 
J Dermatol 2014; 53:e54–5. doi: 10.1111/j.1365-4632.2012. 
05481.x. 
11. Sawamura D, Nakano H, Matsuzaki Y. Overview of 
epidermolysis bullosa. J Dermatol 2010; 37:214–19. doi: 
10.1111/j.1346-8138.2009.00800.x.
